Viscient Biosciences: Funding, Investors & Team (Sep 2026)
Viscient Biosciences is a biotechnology company working at the intersection of human 3D tissue technology and multi-omics (genomics, transcriptomics, metabolomics) analysis to develop drugs across a range of therapeutic areas, with an initial focus in non-alcoholic steatohepatitis (NASH,“fatty liver disease”). Founded and staffed by a team composed of former Organovo and Ardea Biosciences scientists and entrepreneurs, Viscient is driving a revolution in drug discovery, overthrowing the old paradigm of discovery in animal models.
Viscient Biosciences has raised $1.0M across 1 funding round on record, the most recent a Debt Financing of $1.0M announced in Sep 2021.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Viscient Biosciences Company Profile and Key Stats
Latest funding round on record: Sep 2021.
Viscient Biosciences Funding Rounds
Viscient Biosciences Founders and Leadership Team
No contact details are on record for this team yet.
Viscient Biosciences Funding Compared to Other Biotechnology Startups
Viscient Biosciences' latest round of $1.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Viscient Biosciences in Biotechnology and San Diego
Companies Similar to Viscient Biosciences
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Viscient Biosciences Funding FAQs
What does Viscient Biosciences do?
Viscient Biosciences is a biotechnology company working at the intersection of human 3D tissue technology and multi-omics (genomics, transcriptomics, metabolomics) analysis to develop drugs across a range of therapeutic areas, with an initial focus in non-alcoholic steatohepatitis (NASH,“fatty liver disease”). Founded and staffed by a team composed of former Organovo and Ardea Biosciences scientists and entrepreneurs, Viscient is driving a revolution in drug discovery, overthrowing the old paradigm of discovery in animal models.
How much funding has Viscient Biosciences raised?
Viscient Biosciences has raised $1.0M across 1 round on record. The most recent is a Debt Financing of $1.0M announced in Sep 2021.
When did Viscient Biosciences last raise funding?
Viscient Biosciences' most recent funding round on record is a Debt Financing of $1.0M, announced in Sep 2021.
Who is the CEO of Viscient Biosciences?
Keith Murphy is listed as CEO at Viscient Biosciences.
Where is Viscient Biosciences headquartered?
Viscient Biosciences is based in San Diego, California, United States.
How many employees does Viscient Biosciences have?
Viscient Biosciences is in the 1-10 employee band.
How does Viscient Biosciences' funding compare to other Biotechnology startups?
Viscient Biosciences' latest round of $1.0M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Viscient Biosciences Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Viscient Biosciences is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.